Lucid Diagnostics specializes in the early detection and prevention of highly lethal esophageal conditions, specifically focusing on Barrett's esophagus, which is a serious precancerous change in the lining of the lower food tube, and early-stage esophageal adenocarcinoma (esophageal cancer). Its clinical testing procedures target individuals suffering from chronic gastroesophageal reflux disease (GERD) and other established risk factors to identify cellular abnormalities long before invasive malignancies develop.